Efficacy and Safety of the Proposed Ustekinumab Biosimilar BAT2206 vs Reference Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis
J Am Acad Dermatol 2024 Nov 24;[EPub Ahead of Print], X Man, K Zaharieva, G Pulka, A Zebrowska, Y Deng, L Mekokishvili, X Yang, Y Qi, C Gu, Q Dong, M ZhengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.